Hematology

Latest News

Modern Medical Technologies | Image credit: Prostock-studio - stock.adobe.com
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

August 16th 2025

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Dr Thomas Marsland on CMS' CAR T-Cell Therapy Reimbursement Plan
June 21st 2019

Dr Thomas Marsland on CMS' CAR T-Cell Therapy Reimbursement Plan

Thomas Marsland, MD, medical oncologist, discusses his take on the CAR T-cell therapy reimbursement plan put forward by CMS.
Isatuximab Combination Improves PFS in Relapsed, Refractory MM
June 15th 2019

Isatuximab Combination Improves PFS in Relapsed, Refractory MM

Samantha DiGrande
According to results from a randomized phase 3 trial presented at the American Society of Clinical Oncology’s recent annual meeting, the addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improvement progression-free survival (PFS) and the overall response rate (ORR) in patients with relapsed or refractory multiple myeloma (RRMM).
Survival of Patients With Multiple Myeloma Has Continued to Improve
June 13th 2019

Survival of Patients With Multiple Myeloma Has Continued to Improve

Wallace Stephens
Survival of patients with multiple myeloma has continued to improve as treatments have evolved over time.
Multimorbidity, Insurance Status May Affect Survival Rates of Patients With Multiple Myeloma
June 8th 2019

Multimorbidity, Insurance Status May Affect Survival Rates of Patients With Multiple Myeloma

Wallace Stephens
According to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting, multimorbidity, insurance status, and income may affect survival rates of patients with multiple myeloma.
5 Takeaways From ASCO's Annual Meeting
June 7th 2019

5 Takeaways From ASCO's Annual Meeting

Samantha DiGrande
The American Society of Clinical Oncology recently held its annual meeting in Chicago, Illinois. The meeting brought together oncologists, payers, and other stakeholders to discuss the latest updates and therapeutic advances in cancer care. Here are 5 of the biggest takeaways from the meeting.
Adding Daratumumab to Standard Treatment Lowered the Risk of Death, Disease Progression in Patients With Multiple Myeloma
May 31st 2019

Adding Daratumumab to Standard Treatment Lowered the Risk of Death, Disease Progression in Patients With Multiple Myeloma

Wallace Stephens
The addition of daratumumab to standard treatment of lenalidomide and dexamethasone for patients with multiple myeloma, who were ineligible for autologous stem-cell transplant, was found to significantly lower the risk of disease progression or death compared with those who only received standard treatment.
Patients With Prior Hematologic Malignancy at Increased Risk for Head and Neck Cancer, Study Finds
May 31st 2019

Patients With Prior Hematologic Malignancy at Increased Risk for Head and Neck Cancer, Study Finds

Samantha DiGrande
According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with patients without a prior hematologic malignancy.
Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?
May 25th 2019

Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?

Wallace Stephens
Analysis of findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study found no association between sickle cell trait and cognitive impairment.
Lenalidomide Beats Standard of Care in Smoldering MM
May 23rd 2019

Lenalidomide Beats Standard of Care in Smoldering MM

Samantha DiGrande
As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, according to new research that will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois, held May 31 to June 4, early treatment of smoldering MM may delay progression to full-blown disease.
Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL
May 16th 2019

Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL

Jaime Rosenberg
Venetoclax (Venclexta) has received FDA approval in combination with obinutuzumab (Gazyva) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), offering a chemotherapy-free regimen for patients with previously untreated disease.
Finding the Trigger That Sets Off Growth of Hodgkin Lymphoma Cells
May 16th 2019

Finding the Trigger That Sets Off Growth of Hodgkin Lymphoma Cells

Mary Caffrey
Cure rates for Hodgkin lymphoma are high, but survivors may live for decades with side effects from chemotherapy. Finding a new treatment target could lead to fewer toxic effects.
Study Identifies New Therapy Target For Blood Cancers in Mitochondria of Cancer Cells
May 11th 2019

Study Identifies New Therapy Target For Blood Cancers in Mitochondria of Cancer Cells

Jaime Rosenberg
Researchers have identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers.
Triple-Therapy Combo Without Chemo to Be Studied in DLBCL
May 10th 2019

Triple-Therapy Combo Without Chemo to Be Studied in DLBCL

Mary Caffrey
Proof-of-concept studies suggest the treatment that targets CD47 produces a strong response in patients with diffuse large B-cell lymphoma (DLBCL) with fewer adverse effects than current options.
IgL Translocation May Predict Poor Outcomes in Multiple Myeloma
May 2nd 2019

IgL Translocation May Predict Poor Outcomes in Multiple Myeloma

Jaime Rosenberg
DNA rearrangement may be the key to predicting poor outcomes in high-risk patients with multiple myeloma, according to a new study.
Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma
May 2nd 2019

Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma

Mary Caffrey
Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.
A Slower, Gentler CAR T-Cell Therapy? USC Says a Small Study Shows It Could Work
April 25th 2019

A Slower, Gentler CAR T-Cell Therapy? USC Says a Small Study Shows It Could Work

Mary Caffrey
Modifications to the engineering of the chimeric antigen receptor (CAR) mean that the patient produces fewer cytokines and has time to clear them before they build up in the bloodstream.
CMS Proposes Increased Reimbursement for CAR T-Cell Therapy, Price Hikes for Rural Hospitals
April 24th 2019

CMS Proposes Increased Reimbursement for CAR T-Cell Therapy, Price Hikes for Rural Hospitals

Jaime Rosenberg
As part of CMS’ FY 2020 Medicare Hospital Inpatient Prospective Payment System and Long-Term Acute Care Hospital Prospective Payment System Proposed Rule and Request for Information, the agency is proposing an increase in how much it reimburses hospitals for chimeric antigen receptor (CAR) T-cell therapy, as well as wage index hikes for rural hospitals.
Foundation Launches Investment Fund to Speed Multiple Myeloma Treatments
April 16th 2019

Foundation Launches Investment Fund to Speed Multiple Myeloma Treatments

AJMC Staff
The investment fund spun off from the Multiple Myeloma Research Foundation will start at $50 million and will be self-sustaining, focusing on early-stage biotech companies.
Peripheral Neuropathy Significantly Adds to Cost Burden of Multiple Myeloma
April 16th 2019

Peripheral Neuropathy Significantly Adds to Cost Burden of Multiple Myeloma

Jaime Rosenberg
Among patients with multiple myeloma treated with older proteasome inhibitors, those who developed peripheral neuropathy (PN) had significantly higher costs, suggesting that newer therapies may maintain effective treatment while lowering the economic and disease burden of PN in these patients.
Experimental Cancer Vaccine Shrinks Tumors in Form of Non-Hodgkin Lymphoma
April 13th 2019

Experimental Cancer Vaccine Shrinks Tumors in Form of Non-Hodgkin Lymphoma

Mary Caffrey
A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.
Carfilzomib Regimen Safe, Effective in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
April 11th 2019

Carfilzomib Regimen Safe, Effective in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Jaime Rosenberg
Assessing 4 dose levels of carfilzomib, researchers have determined that the drug, in combination with thalidomide and low-dose dexamethasone, is highly safe and effective in transplant-eligible patients with newly diagnosed multiple myeloma.
Site Logo
April 6th 2019

Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg

Mary Caffrey
Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, is harmful to both sides of the doctor-patient relationship, according to Lee B. Schwartzberg, MD, medical director of the West Cancer and Research Institute, who spoke at the 2019 Community Oncology Conference, held in Orlando, Florida.
Study Identifies High Rates of Adherence to IMIDs Among Patients With Multiple Myeloma
April 6th 2019

Study Identifies High Rates of Adherence to IMIDs Among Patients With Multiple Myeloma

Jaime Rosenberg
A study of patients with multiple myeloma in a real-world setting found that adherence to immunomodulatory drugs (IMIDs) is high across all 3 options of the drugs.
Genomic Analysis of High-Risk Leukemia Finds Nearly Half of Cases May Respond to Precision Therapy
March 30th 2019

Genomic Analysis of High-Risk Leukemia Finds Nearly Half of Cases May Respond to Precision Therapy

Mary Caffrey
A comprehensive genomic analysis of acute erythoid leukemia (AEL) found that 45% of patients had mutations in signaling pathways that drive uncontrolled cell growth, and evidence shows these leukemias may respond to existing precision treatments.
Patient Preferences Should Be Considered for Treatment of Relapsed or Refractory Multiple Myeloma
March 30th 2019

Patient Preferences Should Be Considered for Treatment of Relapsed or Refractory Multiple Myeloma

Jaime Rosenberg
A study consisting of interviews and focus groups among patients with relapsed or refractory multiple myeloma brought attention to what patients value about their treatment.
FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality
March 22nd 2019

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality

Samantha DiGrande
This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.
Site Logo
March 21st 2019

NCCN Panel Digs Into Reality of CAR T-Cell Reimbursement

Mary Caffrey
A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.
Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?
March 14th 2019

Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?

Mary Caffrey
There is concern among stakeholder groups that references to “hospital” could mean that community practices would be unable to be reimbursed by Medicare under a proposed National Coverage Determination.
Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM
March 13th 2019

Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM

Jaime Rosenberg
Pooled data from 2 studies revealed that once-weekly administration of 70 mg/m2 of carfilzomib is as safe and effective in newly diagnosed multiple myeloma (MM) as twice-weekly administration of 36 mg/m2 of the treatment while also providing a more convenient treatment schedule.
Addressing Disparities in End-of-Life Care in Blood Cancers
March 8th 2019

Addressing Disparities in End-of-Life Care in Blood Cancers

Laura Joszt, MA
While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.
<1
...
131415161718192021
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo